Trial Profile

Lenvatinib Combined With Tislelizumab and TACE Applied as Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma With High Risk of Recurrence: Study Protocol of a Monocenter, Single-arm, Open Label Clincal Trial

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 19 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Epirubicin (Primary) ; Lenvatinib (Primary) ; Oxaliplatin (Primary) ; Tislelizumab (Primary)
Indications Liver cancer
Focus Therapeutic Use

11 Feb 2025 Planned End Date changed from 1 Mar 2026 to 31 Dec 2025.
11 Feb 2025 Planned primary completion date changed from 1 May 2025 to 31 Dec 2025.
04 Jun 2024 Results (n=19) assessing efficacy and safety of Neoadjuvant tislelizumab combined with lenvatinib plus transcatheter arterial chemoembolization in resectable hepatocellular carcinoma with high-risk of recurrence presented at the 60th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com